Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07010692 · ClinicalTrials.gov registry record · Phase 1
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
A Phase 1 study of Squamous Cell Carcinoma and Skin Cancer, sponsored by Bruce Robinson, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07010692: Recruiting Phase 1 study of Squamous Cell Carcinoma and Skin Cancer, sponsored by Bruce Robinson, MD.
NCT07010692 is a Phase 1 study of Squamous Cell Carcinoma and Skin Cancer that is actively recruiting participants, run by Bruce Robinson, MD. The registered enrollment target is 100 participants, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07010692, a Phase 1 study of Squamous Cell Carcinoma and Skin Cancer, is actively recruiting participants, sponsored by Bruce Robinson, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Primary Outcome
Participants will be monitored at 1 month post-procedure then biannually thereafter for 5 years. Site with be observed for clinical recurrence. Optional biopsy at each visit.
Conditions Studied
Interventions
- DRUG Tirbanibulin ointment 1%
- DEVICE non-ablative fractional laser
Study Locations (1)
New York
- Bruce Robinson, MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
What NCT07010692 shows while recruiting
NCT07010692 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target.
The record links to 4 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Tirbanibulin ointment 1% is the first listed.
NCT07010692 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07010692 about?
NCT07010692 is a clinical study titled "Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment". The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, ...
What is the current status of trial NCT07010692?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-05-16. Estimated completion is 2030-06.
What conditions does trial NCT07010692 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Skin Cancer, Keratinocyte Carcinoma, Basal Cell Carcinomas.
What interventions are being tested in trial NCT07010692?
The interventions under investigation include: Tirbanibulin ointment 1% (DRUG), non-ablative fractional laser (DEVICE).
Who is sponsoring clinical trial NCT07010692?
This trial is sponsored by Bruce Robinson, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07010692 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07010692's enrollment target sits among peer trials
100 12th of 47 higher than 36 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
-
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
ACTIVE NOT RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Pembrolizumab in Combination With CRT for LA-SCCHN
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI